Clinical Trials Logo

Walking Impairment clinical trials

View clinical trials related to Walking Impairment.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03567057 Completed - Multiple Sclerosis Clinical Trials

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Start date: July 18, 2018
Phase: Phase 3
Study type: Interventional

This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).

NCT ID: NCT03436199 Completed - Multiple Sclerosis Clinical Trials

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Start date: March 29, 2018
Phase: Phase 3
Study type: Interventional

This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.

NCT ID: NCT02471222 Completed - Multiple Sclerosis Clinical Trials

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Start date: May 2015
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.